10-Q: Teva Reports Strong Q2 2025 Profit Growth Amid Strategic Divestitures and Debt Reduction

Teva Pharmaceutical Industries Limited announced a significant increase in operating income and net income for the second quarter of 2025, driven by robust performance in its U.S. segment and strategic debt management, despite a slight revenue decrease in local currency terms.

Summary

• Net revenues for Q2 2025 were $4,176 million, flat in U.S. dollars, and decreased 1% in local currency terms compared to Q2 2024.
• Net revenues for the first six months of 2025 were $8,067 million, an increase of 1% compared to the first six months of 2024.
• Operating income for Q2 2025 was $455 million, a significant improvement from an operating loss of $5 million in Q2 2024.
• Net income attributable to Teva for Q2 2025 was $282 million, compared to a net loss of $846 million in Q2 2024.
• Net income attributable to Teva for the first six months of 2025 was $497 million, compared to a net loss of $985 million in the first six months of 2024.
• Gross profit margin for Q2 2025 was 50.3%, up from 48.6% in Q2 2024.
• Research and Development (R&D) expenses decreased by 9% in Q2 2025 to $244 million.
• Total debt decreased to $17,227 million as of June 30, 2025, from $17,783 million as of December 31, 2024.
• Cash flow generated from operating activities for Q2 2025 was $227 million, up from $103 million in Q2 2024.
• Free cash flow for Q2 2025 was $476 million, up from $324 million in Q2 2024.
• The divestment of the business venture in Japan was completed on March 31, 2025.
• The company announced its intention to divest its API business, which has been classified as held for sale.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial improvements in Q2 2025, including a return to net income and operating profit, increased gross margins, and significant debt reduction. Growth in key innovative products is positive. However, challenges remain with declining generic revenues in some segments, ongoing substantial litigation, and macroeconomic uncertainties, which temper the overall positive outlook.

Positives

• Operating income significantly improved to $455 million in Q2 2025 from a $5 million loss in Q2 2024, and to $975 million in H1 2025 from a $223 million loss in H1 2024.
• Net income attributable to Teva turned positive at $282 million in Q2 2025, compared to a net loss of $846 million in Q2 2024, and $497 million in H1 2025 compared to a net loss of $985 million in H1 2024.
• Gross profit margin increased to 50.3% in Q2 2025 from 48.6% in Q2 2024, mainly due to a favorable product mix, primarily driven by higher revenues from AUSTEDO.
• The U.S. segment generated revenues of $2,151 million (up 2%) and segment profit of $706 million (up 12%) in Q2 2025.
• Key innovative products showed strong growth in the U.S. segment in Q2 2025: AUSTEDO revenues increased by 22% to $495 million, AJOVY revenues increased by 53% to $63 million, and UZEDY revenues increased by 120% to $54 million.
• Total debt decreased by $556 million from December 31, 2024, to June 30, 2025, improving financial leverage to 72% from 77%.
• Cash flow generated from operating activities increased to $227 million in Q2 2025 from $103 million in Q2 2024, and free cash flow increased to $476 million from $324 million.
• Successfully launched EPYSQLI (eculizumab-aagh), a biosimilar to Soliris, in the U.S. in April 2025.
• FDA approved SELARSDI (ustekinumab-aekn) as interchangeable with Stelara in all presentations matching the reference product, effective April 30, 2025.
• FDA accepted the supplemental Biologics License Application (sBLA) for AJOVY to expand its indication to include children and adolescents in April 2025.
• Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) were announced in May 2024, with additional safety and efficacy results planned for H2 2025.
• Initiated IND-enabling studies of BD9 for atopic dermatitis and asthma in May 2025, and a Phase 1 clinical trial for TEV-287 for Parkinson's disease in Q2 2025.
• Reached a settlement on the metformin class action in December 2024, resolving all plaintiffs' claims against Teva.
• Finalized nationwide opioid settlement agreement with states and litigating subdivisions in June 2023, and with the City of Baltimore in September 2024.
• The court granted final approval for the proposed class settlement agreement with U.S. hospitals and other healthcare providers regarding opioid-related claims in March 2025.

Negatives

• Revenues in local currency terms decreased by 1% in Q2 2025, primarily due to lower revenues from generic products in the International Markets segment (down 16% in local currency) associated with the divestment of the Japan business venture.
• Generic product revenues in the U.S. segment decreased by 6% in Q2 2025, mainly due to increased competition for lenalidomide capsules (generic Revlimid) and liraglutide injection (authorized generic Victoza).
• COPAXONE revenues decreased by 23% in the U.S. and 6% in Europe (11% in local currency) in Q2 2025 due to market share erosion and competition from alternative therapies and generic glatiramer acetate products.
• API sales to third parties decreased by 11% in Q2 2025 due to lower demand and timing of shipments.
• Legal settlements and loss contingencies increased to $166 million in Q2 2025 from $83 million in Q2 2024, mainly due to updates to opioid settlement provisions and a provision for QVAR antitrust litigation.
• Negative impact from foreign exchange derivatives recognized under revenues was $32 million in Q2 2025, compared to a negative impact of $2 million in Q2 2024.
• General and Administrative (G&A) expenses increased by 8% in Q2 2025 to $305 million, mainly due to costs related to optimization activities and transformation programs.
• Sustainability-linked bonds may incur higher interest rates (0.100%-0.375% per annum) or a one-time premium payment (0.15%-0.45% of principal) if Teva fails to achieve certain sustainability performance targets.
• The agreement with the Israeli Tax Authorities (ITA) includes a provision for an additional 5%-7% corporate tax payment on future dividends or equity repurchases, up to $500 million.
• Operations in Argentina and Turkey are subject to highly inflationary accounting treatment.

Risks

• Ability to successfully compete in the marketplace, including substantial dependence on generic products, concentration of customer base, commercial alliances among customers, and competition from other pharmaceutical companies.
• Changes in regulatory policy that may result in additional costs and delays for generic medicines.
• Delays in launches of new generic products.
• Ability to develop and commercialize additional pharmaceutical products and achieve expected results from investments in the product pipeline.
• Competition for innovative medicines.
• Ability to successfully execute the 'Pivot to Growth' strategy, including expanding innovative and biosimilar pipelines, profitably commercializing the portfolio, sustaining and focusing the generic medicines portfolio, and executing organizational transformation to achieve expected cost savings.
• Effectiveness of patents and other measures to protect intellectual property rights, including potential challenges to Orange Book patent listings.
• Significant indebtedness, which may limit the ability to incur additional indebtedness, engage in additional transactions, or make new investments.
• Potential need to raise additional funds in the future, which may not be available on acceptable terms or at all.
• Impact of global economic conditions and other macroeconomic developments, and governmental/societal responses thereto.
• Widespread outbreak of an illness or any other communicable disease, or any other public health crisis.
• Effectiveness of optimization efforts.
• Significant disruptions of information technology systems, including cybersecurity attacks and breaches of data security.
• Interruptions in the supply chain or problems with internal or third-party manufacturing.
• Challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel.
• Ability to attract, hire, integrate, and retain highly skilled personnel.
• Ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions.
• Prospects and opportunities for growth if assets or business units are sold and plants/facilities are closed or divested, as well as the ability to successfully and cost-effectively consummate such sales and divestitures, including the planned divestiture of the API business.
• Failure to comply with complex legal and regulatory environments.
• Effects of governmental and civil proceedings and litigation, including opioid litigation, generic drug antitrust litigation, and COPAXONE antitrust litigation.
• Effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement, and coverage, including as a result of the 'One Big Beautiful Bill Act' (OBBBA) and U.S. Executive Orders intended to reduce prescription medicine prices.
• Increased legal and regulatory action in connection with public concern over the abuse of opioid medications.
• Ability to timely make payments required under the nationwide opioids settlement agreement and provide generic Narcan.
• Scrutiny from competition and pricing authorities around the world, including compliance with the deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ).
• Potential liability for intellectual property right infringement.
• Product liability claims, including those related to nitrosamine impurities in valsartan, losartan, metformin, and ranitidine products.
• Failure to comply with complex Medicare, Medicaid, and other governmental programs reporting and payment obligations.
• Compliance with sanctions and trade control laws.
• Environmental risks, including liability for investigation and remediation of hazardous substance releases and natural resource damages (e.g., India penalty).
• Impact of Environmental, Social and Governance (ESG) issues.
• Impact of the state of war declared in Israel and military activity in the Middle East on operations, facilities, employees, and economic, social, and political stability of Israel.
• Exposure to currency fluctuations and restrictions, as well as credit risks.
• Potential impairments of long-lived assets.
• Potential significant increases in tax liabilities, including the effect on the overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in business.
• Exposure to changes in international trade policies, including the imposition of tariffs.
• Impact of any future failure to establish and maintain effective internal control over financial reporting.
• Uncertainty regarding the ultimate timing or structure of a potential divestiture of the API business.
• Interest rate adjustments and potential one-time premium payments related to sustainability-linked bonds if sustainability performance targets are not met.
• Ongoing litigation regarding Eli Lilly & Co.'s galcanezumab product and Amarin's icosapent ethyl product.
• Litigation against Corcept Therapeutics, Inc. and Optime Care Inc. regarding Korlym (mifepristone) drug product.
• Adverse resolution of any lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on reputation, business, results of operations, and cash flows.
• Uncertainty of outcome and no guarantee that Teva will be granted its requested relief in gain contingencies.
• The lawsuit challenging the processes and guidance used by the U.S. Government to implement the Inflation Reduction Act (IRA) and its Drug Price Negotiation Program.

Future Outlook

Teva expects to continue executing its 'Pivot to Growth' strategy, focusing on expanding its innovative portfolio, aligning capital allocation to high-value activities, and optimizing its organization and operations for cost savings. The company's Transformation programs are projected to reduce approximately 8% of its total workforce by the end of 2027. Key pipeline developments include plans to initiate Phase 3 development for duvakitug in inflammatory bowel disease in the second half of 2025, pending regulatory discussions, and the presentation of additional safety and efficacy results for olanzapine LAI in the second half of 2025. Teva is also pursuing additional submissions for AUSTEDO in various markets. The company is evaluating the impact of the 'One Big Beautiful Bill Act' and OECD BEPS Pillar Two rules on its financial statements but does not currently anticipate a material impact from either in the foreseeable future. Teva expects to maintain sufficient cash resources for debt service and other financial obligations within the next year.

Management Comments

• We continued to execute on the four key pillars of our Pivot to Growth strategy, announced in May 2023, and entered into its second phase.
• During this second phase of Accelerate Growth, we expect to focus on growing our innovative portfolio, aligning capital allocation to invest in the highest value activities, and optimizing our organization and operations for cost savings.
• Under Teva's Transformation programs announced on May 7, 2025, we expect to achieve such cost savings through a variety of initiatives including examining practices and efficiencies in methods of working, reduction in headcount and optimizing external spend in the following years.

Industry Context

The pharmaceutical industry continues to be characterized by intense competition, particularly in the generics and biosimilars sectors, which contributes to price erosion for off-patent products. Teva's strategy emphasizes innovative products like AUSTEDO, AJOVY, and UZEDY as crucial growth drivers to offset declines in older branded products such as COPAXONE and certain generics. The industry is facing increasing regulatory scrutiny on drug pricing, exemplified by the U.S. Government's price-setting discussions for AUSTEDO and AUSTEDO XR under the Inflation Reduction Act. Geopolitical conflicts, including the ongoing situations in Russia-Ukraine and Israel-Middle East, present persistent risks to global supply chains and operational stability for multinational pharmaceutical companies. The company's focus on biosimilars, with recent approvals and launches like SIMLANDI, SELARSDI, and EPYSQLI, aligns with a broader industry trend towards developing more affordable alternatives to complex biologics.

Comparison to Industry Standards

• The market for Multiple Sclerosis (MS) treatments, where COPAXONE competes, continues to evolve with the approval of generic versions of COPAXONE and the increasing competition from oral branded and generic treatments such as Tecfidera (dimethyl fumarate) and Gilenya (fingolimod), as well as monoclonal antibodies like Ocrevus, Kesimpta, and Tysabri.
• Teva's total U.S. generic prescription market share (based on trailing twelve months) decreased to 6.9% in Q2 2025 from 7.9% in Q2 2024, indicating a slight decline in its competitive position within the U.S. generics market.
• AJOVY's exit market share in the U.S. subcutaneous injectable anti-CGRP class increased to 31.0% in Q2 2025 from 28.6% in Q2 2024, demonstrating strong competitive positioning and growth within this specific migraine treatment segment.

Management Changes

Corporate Governance

Legal Proceedings

• Opioid Litigation: Over 3,500 complaints filed, with the vast majority resolved. Finalized nationwide settlement agreement with states and litigating subdivisions in June 2023 for up to $4.25 billion (including product supply). Settled with the City of Baltimore in September 2024 for $80 million. Final approval for the proposed class settlement agreement with U.S. hospitals and other healthcare providers was granted in March 2025 for up to $126 million cash and $49 million in generic Narcan. Estimated cash payments for all opioid settlements are $419 million in 2025, $363 million in 2026, $364 million in 2027, $385 million in 2028, and $339 million in 2029. A provision of $5,002 million for legal settlements and loss contingencies was recorded as of June 30, 2025.
• Generic Drug Antitrust Litigation: Teva USA was indicted for criminal felony Sherman Act violations in August 2020 and entered into a 3-year deferred prosecution agreement (DPA) with the DOJ in August 2023, admitting violations, agreeing to divest pravastatin, donate $50 million worth of clotrimazole and tobramycin, and pay a $225 million fine over 5 years. Settled civil allegations with the DOJ Civil Division for $25 million in October 2024. Ongoing civil actions by attorneys general of 49 states, DC, Puerto Rico, and US Virgin Islands, with some settlements reached. Numerous class action complaints by direct and indirect purchasers are consolidated in the Pennsylvania MDL. Walmart Inc. and Southwest Airlines, Inc. filed new lawsuits in Q2 2025.
• COPAXONE Antitrust Litigation (Europe): The European Commission issued a final decision in October 2024, alleging abuse of dominant position and imposing a fine of euro 462.6 million. Teva filed an appeal against the decision in January 2025.
• COPAXONE Antitrust Litigation (U.S.): Mylan Pharmaceuticals and purported purchasers filed claims in U.S. District Courts. Teva moved to dismiss, and a Special Master issued reports recommending dismissal of several aspects of claims.
• Carvedilol Patent Infringement (GSK): The Court of Appeals for the Federal Circuit reinstated a $235.5 million jury verdict against Teva. The U.S. Supreme Court denied Teva's appeal for a rehearing. A trial regarding certain equitable issues remains pending.
• Nitrosamine Impurities Product Liability: Multi-District Litigations (MDLs) are pending for valsartan/losartan and ranitidine. Ranitidine claims against Teva and other generic manufacturers have been dismissed on preemption and other grounds and are currently on appeal. The metformin class action was settled in December 2024.
• Extended-Release Venlafaxine (Generic Effexor XR) Antitrust: Teva and the Indirect Purchaser Plaintiffs (IPPs) reached an agreement to resolve the IPPs' claims, which was granted preliminary approval by the court in March 2025.
• Lamotrigine (Generic Lamictal) Antitrust: Direct purchasers who were denied class certification filed suit as individual plaintiffs. Discovery of the newly added individual plaintiffs is ongoing.
• Niaspan (Extended Release Niacin) Antitrust: A multidistrict litigation has been established. The U.S. District Court's denial of the indirect purchasers' motion for class certification was affirmed by the Court of Appeals. Litigation remains ongoing.
• Modafinil Antitrust (Europe): The European Commission issued a final decision in November 2020, imposing fines totaling euro 60.5 million. Teva appealed, and the advocate general to the European Court of Justice issued a non-binding opinion recommending dismissal of Teva's appeal in March 2025.
• HIV Medicines Antitrust: Lawsuits challenged settlement agreements Teva entered into with Gilead. A jury in June 2023 issued a verdict in favor of Teva and Gilead, rejecting all remaining plaintiffs' claims. The plaintiffs appealed.
• DOJ Patient Assistance Program (PAP) Litigation: A civil action was brought in August 2020 alleging Anti-Kickback Statute violations. Teva entered into a settlement agreement with the DOJ in October 2024 to resolve these claims for $425 million over 6 years. The case was dismissed with prejudice in November 2024. Related actions by Humana and United Healthcare are ongoing. A putative class action by MSP Recovery-related entities was dismissed in April 2025.
• EpiPen (epinephrine injection) and NUVIGIL (armodafinil) Antitrust: Plaintiffs filed a complaint alleging antitrust violations. The court granted Teva's motion in part, dismissing RICO claims and certain state law claims, but denied the motion regarding antitrust claims. Discovery is bifurcated.
• QVAR Antitrust: Putative class action complaints were filed alleging anticompetitive conduct. The court dismissed claims related to sham litigation and certain state antitrust/consumer protection claims but permitted the case to proceed on other allegations. Teva recognized a provision for this matter in Q2 2025.
• Orange Book Patents Investigation (FTC): Teva received a civil investigative demand in June 2024 seeking documents and information regarding an investigation related to patents listed in the FDA's Orange Book in connection with certain inhaler products.
• Irvine Manufacturing Practices Investigation (DOJ): Teva received a civil investigative demand in October 2024 requesting documents and information related to manufacturing practices at its former Irvine, California facility.
• Eli Lilly & Co. (Galcanezumab) Patent Infringement: A jury trial resulted in a verdict in Teva's favor, awarding $176.5 million in damages, but the U.S. District Court reversed the verdict, finding Teva's method of treatment patents invalid. Teva appealed this ruling, and the appeal hearing has been set for September 5, 2025.
• Amarin (Icosapent Ethyl) Antitrust: Teva filed a lawsuit in March 2024 alleging a scheme to lock up the supply of icosapent ethyl. Amarin's motion to enforce the terms of an earlier settlement agreement was denied in December 2024.
• Corcept (Korlym) Antitrust: Teva filed a lawsuit in June 2024 alleging a scheme to stifle generic competition to Korlym. Defendants filed a joint motion to dismiss, which is awaiting decision.
• Israeli Shareholder Litigation: Motions to approve derivative actions seeking monetary damages against certain past and present directors and officers have been filed in Israeli Courts, alleging negligence and recklessness, and have been stayed pending U.S. litigation.
• Environmental Matters (India): The National Green Tribunal Principal Bench, New Delhi, issued an order against Teva's subsidiary in India, Teva API India Private Limited, assessing a penalty of $1.4 million. Teva filed an appeal, which the Supreme Court accepted in April 2025.
• Inflation Reduction Act (IRA) Challenge: Teva filed a complaint against CMS and HHS in the U.S. District Court for the District of Columbia in January 2025, challenging the processes and guidance used to implement the Drug Price Negotiation Program.

Stakeholder Impact

• Shareholders: Experienced positive impact from increased net income, operating income, and debt reduction. However, the ability to pay dividends remains constrained by accumulated deficit, and share price is subject to ongoing litigation outcomes and strategic divestitures.
• Employees: Affected by 'Transformation programs' which include 'headcount reductions' (approximately 8% of the total workforce by the end of 2027). Performance incentive payments for 2024 were made.
• Customers: Benefit from new product launches (generics, biosimilars) and the availability of innovative products (UZEDY, AUSTEDO, AJOVY). Potential drug price changes due to the Inflation Reduction Act (IRA) could impact affordability.
• Suppliers: Some suppliers participate in supply chain finance agreements, allowing them to sell accounts receivable to financial institutions. Teva has also obtained more favorable payment terms from many vendors.
• Creditors: Benefit from debt reduction and improved financial leverage. However, sustainability-linked bonds introduce a risk of higher interest rates or premium payments if ESG targets are not met.
• Regulatory Authorities: Teva continues to engage with regulatory bodies for product approvals and sBLAs. The company remains subject to ongoing investigations and litigation from the DOJ, FTC, European Commission, and various state attorneys general.

Next Steps

• Sanofi and Teva plan to initiate Phase 3 development in inflammatory bowel disease for duvakitug in the second half of 2025, pending regulatory discussions.
• Additional safety and efficacy results for olanzapine LAI are planned to be presented in the second half of 2025.
• Teva continues to pursue additional submissions for AUSTEDO in various other markets.
• Teva expects to achieve cost savings through its Transformation programs, including headcount reductions, by the end of 2027.
• The price-setting process for AUSTEDO and AUSTEDO XR under the Inflation Reduction Act (IRA) is ongoing, with revised prices expected to be effective January 1, 2027.
• Teva's first trial for the valsartan product may occur no earlier than in the first quarter of 2026.
• The appeal hearing for the Eli Lilly & Co. case is set for September 5, 2025.
• The appeal hearing for the Canadian opioid cases is scheduled for December 2025.
• Multiple groups of motions for summary judgment in the attorneys general's third complaint (generic drug antitrust litigation) will be filed during 2025.
• Teva's appeal against the European Commission's COPAXONE antitrust decision remains pending.
• The Supreme Court accepted the appeal filed by Teva's subsidiary regarding the India environmental penalty, and it will be scheduled for hearing(s) in due course.

Key Dates

Recommendation

While Teva has demonstrated significant financial improvement in Q2 2025, including a return to profitability, increased gross margins, and substantial debt reduction, the company continues to face considerable ongoing litigation risks with potentially large monetary penalties. The 'Pivot to Growth' strategy is progressing with innovative product growth and biosimilar launches, but the generics segment faces continued competition and revenue declines in some areas. The long-term impact of drug pricing regulations (IRA) and geopolitical instability remains uncertain. Given this mix of positive operational execution and persistent legal and market challenges, a 'hold' recommendation is appropriate for a seasoned investor, suggesting continued monitoring of litigation outcomes, debt management, and the success of the innovative pipeline.

Keywords

Pharmaceuticals, Generics, Biosimilars, Innovative Medicines, Teva, Financial Results, Debt Management, Product Pipeline, AUSTEDO, AJOVY, UZEDY, Opioids, Antitrust Litigation, R&D, Divestiture, API Business, Healthcare, Drug Pricing, Israel, Europe, United States, SEC Filing, 10-Q